(Q37693948)

22 August 2017

1 reference

title

Role of ribavirin in HCV treatment response: now and in the future (English)

1 reference

22 August 2017

1 reference

1 reference

1

Mamta K Jain

1 reference

22 August 2017

Cindy Zoellner

2

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 March 2010

1 reference

Expert Opinion on Pharmacotherapy

22 August 2017

published in

1 reference

22 August 2017

volume

11

1 reference

22 August 2017

issue

4

1 reference

22 August 2017

page(s)

673-683

1 reference

The prevalence of hepatitis C virus infection in the United States, 1999 through 2002

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656560903580001

Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Collaborative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903580001

A phase III study of the safety and efficacy of viramidine versus ribavirin in treatment-naïve patients with chronic hepatitis C: ViSER1 results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903580001

Disposition and metabolic profiles of [14C]viramidine and [14C]ribavirin in rat and monkey red blood cells and liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903580001

Ribavirin, viramidine and adenosine-deaminase-catalysed drug activation: implication for nucleoside prodrug design

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903580001

Modelling how ribavirin improves interferon response rates in hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903580001

Ribavirin mode of action in chronic hepatitis C: from clinical use back to molecular mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903580001

Immunology of hepatitis B virus and hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903580001

Ribavirin upregulates interleukin-12 receptor and induces T cell differentiation towards type 1 in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903580001

Targeted delivery of ribavirin improves outcome of murine viral fulminant hepatitis via enhanced anti-viral activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903580001

The metabolism, pharmacokinetics and mechanisms of antiviral activity of ribavirin against hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903580001

Sindbis virus mutants resistant to mycophenolic acid and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903580001

The structure of inosine 5'-monophosphate dehydrogenase and the design of novel inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903580001

Mechanism of action of ribavirin in the combination treatment of chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903580001

Mutagenic and inhibitory effects of ribavirin on hepatitis C virus RNA polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903580001

Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903580001

Mutagenic effects of ribavirin and response to interferon/ribavirin combination therapy in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903580001

Effect of Ribavirin on the Mutation Rate and Spectrum of Hepatitis C Virus In Vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903580001

Mutagenic effect of ribavirin on hepatitis C nonstructural 5B quasispecies in vitro and during antiviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903580001

Antiviral action of ribavirin in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903580001

Mutation rate of the hepatitis C virus NS5B in patients undergoing treatment with ribavirin monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903580001

Ribavirin up-regulates the activity of double-stranded RNA-activated protein kinase and enhances the action of interferon-alpha against hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903580001

Ribavirin enhances interferon signaling via stimulation of mTOR and p53 activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903580001

Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903580001

Reduced Ribavirin Antiviral Efficacy via Nucleoside Transporter-Mediated Drug Resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903580001

Ribavirin dosing in chronic hepatitis C: application of population pharmacokinetic-pharmacodynamic models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903580001

Intestinal absorption of ribavirin is preferentially mediated by the Na+-nucleoside purine (N1) transporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903580001

Pharmacokinetics of ribavirin in patients with hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903580001

Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903580001

Dosage of ribavirin in patients with hepatitis C should be based on renal function: a population pharmacokinetic analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903580001

Dosage adjustment of ribavirin based on renal function in Japanese patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903580001

Correlation of serum ribavirin concentration with pretreatment renal function estimates in patients with chronic hepatitis C receiving combination antiviral therapy with peginterferon and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903580001

Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903580001

Early ribavirin pharmacokinetics, HCV RNA and alanine aminotransferase kinetics in HIV/HCV co-infected patients during treatment with pegylated interferon and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903580001

Serum concentrations of ribavirin and pegylated interferon and viral responses in patients infected with HIV and HCV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903580001

Ribavirin Quantification in Combination Treatment of Chronic Hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903580001

Ribavirin uptake by human erythrocytes and the involvement of nitrobenzylthioinosine-sensitive (es)-nucleoside transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903580001

Marked elevation of erythrocyte ribavirin levels in interferon and ribavirin-induced anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903580001

Pharmacokinetic/pharmacodynamic and time-to-event models of ribavirin-induced anaemia in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903580001

Evidence that plasma concentration rather than dose per kilogram body weight predicts ribavirin-induced anaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903580001

Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903580001

Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903580001

Prolonged therapy of chronic hepatitis C with ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903580001

Ribavirin monotherapy in patients with chronic hepatitis C: a retrospective study of 95 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903580001

Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903580001

Evaluation of long-term efficacy of interferon alpha-2b and ribavirin in combination in naive patients with chronic hepatitis C: an Italian multicenter experience. Ribavirin-Interferon in Chronic Hepatitis Italian Group Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903580001

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903580001

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903580001

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903580001

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903580001

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903580001

Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903580001

Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903580001

Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903580001

A randomized, prospective trial of ribavirin 400 mg/day versus 800 mg/day in combination with peginterferon alfa-2a in hepatitis C virus genotypes 2 and 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903580001

Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903580001

Ribavirin dose reduction raises relapse rate dose-dependently in genotype 1 patients with hepatitis C responding to pegylated interferon alpha-2b plus ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903580001

Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903580001

Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903580001

High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903580001

Hepatitis C in patients with human immunodeficiency virus infection: diagnosis, natural history, meta-analysis of sexual and vertical transmission, and therapeutic issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903580001

The natural history of hepatitis C virus infection: host, viral, and environmental factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903580001

Evidence that both HIV and HIV-induced immunodeficiency enhance HCV replication among HCV seroconverters

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903580001

Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903580001

Survival of persons with and without HIV infection in Denmark, 1995-2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903580001

Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903580001

Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903580001

Hematologic toxicity associated with interferon-based hepatitis C therapy in HIV type 1-coinfected subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903580001

The anti-hepatitis C agent nitazoxanide induces phosphorylation of eukaryotic initiation factor 2alpha via protein kinase activated by double-stranded RNA activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903580001

Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903580001

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903580001

Telaprevir and peginterferon with or without ribavirin for chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903580001

10.1517/14656560903580001

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference